Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

3.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

5.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K
Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathological, Molecular and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

ACTIN::MITF-rearranged tumor: a distinctive entity or a cutaneous PEComa with MITF alterations? A clinicopathological and molecular study of additional 5 cases.

Virchows Archiv : an international journal of pathology·2026
Same author

CARMN fusions and PDGFRB mutations highlight key differences among cutaneous tumors with myopericytic differentiation.

The Journal of investigative dermatology·2026
Same author

VGLL3-Rearranged Spindle Cell Rhabdomyoblastic Tumor: A Clinicopathologic and Molecular Genetic Study of 18 Cases With Consistently Indolent Behavior.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

An Updated Conceptual Framework for Myoepithelial Tumors of Soft tissues and Bone: Toward a Molecularly Informed Classification.

Seminars in diagnostic pathology·2026
Same author

CRTC1::TRIM11 Cutaneous Tumors With Atypia: Melanoma Mimicry, Aggressive Potential, and Methylation Classifier Limitations.

Genes, chromosomes & cancer·2026
Same journal

Pathobiology and Interactions of the MiTF Signaling Pathways.

Advances in anatomic pathology·2026
Same journal

Diagnosis and Reporting of Intraductal Carcinoma of the Prostate: A Guide for Practising Pathologists With Excerpts From the Genitourinary Pathology Society and the International Society of Urological Pathology Joint Expert Consultation.

Advances in anatomic pathology·2026
Same journal

An Update on Soft Tissue Tumors of the Paratesticular Region.

Advances in anatomic pathology·2026
Same journal

Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management.

Advances in anatomic pathology·2026
Same journal

Hereditary and Familial Tumor Syndromes: When to Think of Them? The Emerging Role of Pathologists as Sentinels of Genetic Cancer Predisposition.

Advances in anatomic pathology·2026
Same journal

From Familial Clustering to a Dedicated Classification: The Historical Recognition of Hereditary Tumor Syndromes in the WHO Classification of Tumors.

Advances in anatomic pathology·2026
See all related articles

Related Experiment Video

Updated: May 20, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

MITF Pathway-Activated Cutaneous Neoplasms.

Michael Michal1, Steven D Billings2, Thomas Brenn3

  • 1Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University Plzen, Czech Republic Bioptical Laboratory Ltd, Pilsen, Czech Republic.

Advances in Anatomic Pathology
|May 19, 2025
PubMed
Summary
This summary is machine-generated.

Several dermal tumors activate the microphthalmia (MITF) pathway via gene fusions, leading to a melanocytic phenotype. Understanding these rare tumors, including clear cell sarcoma, is crucial for diagnosis and treatment.

Keywords:
MITFfusion genesmelanocyticneoplasmskintumor

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K

Related Experiment Videos

Last Updated: May 20, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K

Area of Science:

  • Oncology
  • Genetics
  • Dermatopathology

Background:

  • Dermal tumors can exhibit a melanocytic phenotype due to specific gene fusions.
  • Microphthalmia (MITF) signaling pathway activation is a common mechanism in these tumors.
  • Clear cell sarcoma, characterized by EWSR1 rearrangements, is a well-known example, though rare in the skin.

Purpose of the Study:

  • To provide a comprehensive overview of rare dermal tumors with MITF pathway activation.
  • To highlight the distinguishing features of various fusion-driven cutaneous tumors.
  • To aid in the differential diagnosis of these uncommon neoplasms.

Main Methods:

  • Review of recent scientific literature on cutaneous tumors with gene fusions.
  • Analysis of characteristic genetic alterations (e.g., EWSR1, CRTC1::TRIM11, ACTIN::MITF).
  • Comparison of clinical, histopathologic, and immunophenotypic features.

Main Results:

  • Multiple gene fusions (e.g., CRTC1::TRIM11, ACTIN::MITF, MITF::CREM, MED15::ATF1) have been identified in cutaneous tumors.
  • These tumors share a melanocytic phenotype and MITF pathway activation.
  • Subtle differences in presentation, histology, immunophenotype, and prognosis exist among these entities.

Conclusions:

  • Fusion genes play a significant role in the pathogenesis of a subset of rare dermal tumors.
  • Accurate differentiation requires careful evaluation of multiple clinicopathologic parameters.
  • Further research is needed to fully elucidate the behavior and optimal management of these tumors.